To the Editor We read with interest the article by Jabbour et al1 regarding their phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non–small cell lung cancer (NSCLC). This nonrandomized controlled trial highlights that combined treatment for stage III NSCLC is safe and tolerable, with promising progression-free survival; however, we have some questions.